European Commission Approves Merck's KEYTRUDA (Pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
Portfolio Pulse from Benzinga Newsdesk
The European Commission has approved Merck's KEYTRUDA as a treatment for adults with non-small cell lung cancer at high risk of recurrence. This follows a positive recommendation from the Committee for Medicinal Products for Human Use and is based on results from the Phase 3 KEYNOTE-091 trial.
October 16, 2023 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's KEYTRUDA has been approved by the European Commission as a treatment for high-risk non-small cell lung cancer. This could potentially increase Merck's market share and revenues.
The approval of KEYTRUDA by the European Commission expands Merck's market and could lead to increased sales and revenues. This is likely to have a positive impact on Merck's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100